

Community Onset MRSA Infections in Australia: A Tale of Two Clones

Geoffrey Coombs¹,
 Graeme Nimmo², Julie Pearson¹,
 Samantha Cramer¹ and Keryn Christiansen¹

¹Department of Microbiology and Infectious Diseases
 PathWest Laboratory Medicine – WA
 Royal Perth Hospital

²Division of Microbiology
 Pathology Queensland Central Laboratory

Antimicrobial 2010
 Australian Society for Antimicrobials
 25th February 2010



Community Associated MRSA

First isolated in the Kimberley region of WA (1989) in the aboriginal population. ST8-MRSA-IV (WA MRSA 5) [PVL NEGATIVE]



Udo EE et al
 (1993) *J Hosp Infect* 25, 97-108
 Genetic analysis of community strains of methicillin-resistant *Staphylococcus aureus* in Western Australia


1960 1970 1980 1990 2000

Auckland Region (via Western Samoa) (1992)
 ST30-MRSA-IV (WSPP) [PVL POSITIVE]

World-wide dissemination of community MRSA





Community Associated MRSA





- Papua New Guinea
- Asia
- Europe
- United Kingdom
- Ireland
- Canada
- United States of America
- Central America
- South America





Community Associated MRSA

- Lack risk factors associated with healthcare-associated MRSA
- Skin and soft tissue infections in young people
- Laboratory Findings
 - Susceptible to most non-β-lactam antimicrobials
 - Very rapid growth times
 - Clone types different from healthcare-associated MRSA
 - SCCmec IV (V, VII, VIII)
 - Panton Valentine leukocidin (PVL) [*lukF* and *lukS* genes]
 - Greater clonal diversity







AGAR 2008 Community *S aureus* Surveillance Programme


Community-Associated MRSA Clones
[340 isolates consisting of 22 clones, 62% of MRSA]

ST93-MRSA-IV (Qid MRSA) [180]
ST1-MRSA-IV (WA MRSA-1) [63]
ST1-MRSA-V [1]
ST5-MRSA-IV (WA MRSA-3) [20]
ST73-MRSA-IV (WA MRSA-65) [6]
ST5-MRSA-IV [1]
ST5-MRSA-V [2]
ST8-MRSA-IV (WA MRSA-5)
ST8-MRSA-IV (USA300) [10]
ST834-MRSA-IV (WA MRSA-13) [1]
ST30-MRSA-IV (WSPP) [47]
ST45-MRSA-V (WA MRSA-4) [2]
ST45-MRSA-V (WA MRSA-84) [7]
ST45-MRSA-IV (WA MRSA-23) [2]
ST59-MRSA-IV (WA MRSA-15) [2]
ST59-MRSA-V (Taiwan CA-MRSA) [1]
ST72-MRSA-IV (WA MRSA-44) [2]
ST1304-MRSA-IV (WA MRSA-72) [1]
ST78-MRSA-IV (WA MRSA-2) [18]
ST80-MRSA-IV (European CA-MRSA) [2]
ST86-MRSA-V [1]
ST207-MRSA-V [1]

Healthcare-Associated MRSA clones
[207 isolates consisting of 4 clones, 38% of MRSA]

ST22-MRSA-IV (EMRSA-16) [112]
ST239-MRSA-II (Ausz 2nd and Aus3 EMRSA) [93]
ST5-MRSA-II (New York Japan MRSA or USA100) [1]
ST36-MRSA-II (EMRSA-16 or USA200) [1]

AGAR 2008 Community *S aureus* Surveillance Programme

Qld CA-MRSA (ST93-MRSA-IV) 27.4% of MRSA Community-Associated MRSA Clone	EMRSA-15 (ST22-MRSA-IV) 20.5% of MRSA Healthcare-Associated MRSA clone
	
First identified in Caucasian patients in Ipswich Queensland (Munckhof <i>et al</i> 2003) - boils, bacteraemia, pneumonia	Warninglid 2½ First identified in the Midlands and South-East England in the early 1990s
Epidemic potential Substantial outbreaks (causing boils) in aborigines living in rural NSW (Gosbell <i>et al</i> 2004)	Major HA-MRSA clone in United Kingdom, Ireland, several European countries, New Zealand, Singapore and Australia
Multiple reports of severe infections including necrotising pneumonia (including fatal cases), deep abscesses, osteomyelitis, septic arthritis and bacteraemia	First reported in Australia in 1997 (Pearman <i>et al</i> 1998)
	In Western Australia frequently isolated from patients in long term care facilities and pre-employment screening of healthcare workers from Ireland and the United Kingdom

AGAR 2008 Community <i>S aureus</i> Surveillance Programme	
Qld CA-MRSA (ST93-MRSA-IV) 27.4% of MRSA Community-Associated MRSA Clone	EMRSA-15 (ST22-MRSA-IV) 20.5% of MRSA Healthcare-Associated MRSA clone
Antibiogram: Ciprofloxacin® 0% Erythromycin® 9% Tetracycline® 1% Mupirocin® 0% Fusidic Acid® 0% Rifampicin® 0% Gentamicin® 0% Cotrimoxazole® 1% Clindamycin® 3%	Antibiogram: Ciprofloxacin® 100% Erythromycin® 63% Tetracycline® 3% Mupirocin® <1% Fusidic Acid® <1% Rifampicin® 0% Gentamicin® 0% Cotrimoxazole® 0%
Panton Valentine Leucocidin: Positive	Panton Valentine Leucocidin: Negative

